tbuckley/cabot-search huggingface dataset:
Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy
Authors: Alexander Romanov, Alexander Cherniavskiy, Nataliya Novikova, Alexander Edemskiy, Dmitry Ponomarev, Vitaliy Shabanov, Denis Losik, Dmitry Elesin, Ilya Stenin, Igor Mikheenko, Roman Zhizhov, Evgeny Kretov, Evgeny Pokushalov, Sunny S. Po, Tamila V. Martynyuk, Jonathan S. Steinberg
Journal: Journal of the American College of Cardiology (2020)
Physicians and Social Determinants of Health—Reply
Authors: Thomas L. Schwenk
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Regurgitant Volume/Left Ventricular End-Diastolic Volume Ratio
Authors: Farnaz Namazi, Pieter van der Bijl, Federico Fortuni, Bart J.A. Mertens, Vasileios Kamperidis, Suzanne E. van Wijngaarden, Gregg W. Stone, Jagat Narula, Nina Ajmone Marsan, Alec Vahanian, Victoria Delgado, Jeroen J. Bax
Journal: JACC. Cardiovascular imaging (2020)
The FTO/miR‐181b‐3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer
Authors: Yuanyuan Xu, Shuang Ye, Nan Zhang, Shuhui Zheng, Huatao Liu, Kewen Zhou, Ling Wang, Yue Cao, Peng Sun, Tinghuai Wang
Journal: Cancer Communications (2020)

Abstract Background N6‐methyladenosine (m 6 A) RNA modification has been demonstrated to be a significant regulatory process in the progression of various tumors, including breast cancer. Fat mass and obesity‐associated (FTO) enzyme, initially known as the obesity‐related protein, is the first identified m 6 A demethylase. However, the relationship between FTO and breast cancer remains controversial. In this study, we aimed to elucidate the role and clinical significance of FTO in breast cancer and to explore the underlying mechanism. Methods We first investigated the expression of FTO in breast cancer cell lines and tissues by quantitative reverse transcription‐PCR (qRT‐PCR), Western blotting, and immunohistochemistry. Wound healing assay and Transwell assay were performed to determine the migration and invasion abilities of SKBR3 and MDA‐MB453 cells with either knockdown or overexpression of FTO. RNA sequencing (RNA‐seq) was conducted to decipher the downstream targets of FTO. qRT‐PCR, luciferase reporter assay, and Western blotting were employed to confirm the existence of the FTO/miR‐181b‐3p/ARL5B axis. The biological function of ADP ribosylation factor like GTPase 5B (ARL5B) in breast cancer cells was evaluated by wound healing assay and Transwell invasion assay. Results High FTO expression was observed in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer, predicting advanced progression (tumor size [ P &lt; 0.001], nuclear grade [ P = 0.001], peritumoral lymphovascular invasion [ P &lt; 0.001), lymph node metastasis [ P = 0.002], and TNM stage [ P = 0.001]) and poor prognosis. Moreover, FTO promoted cell invasion and migration in vitro . Mechanistically, RNA‐seq and further confirmation studies suggested that FTO up‐regulated ARL5B by inhibiting miR‐181b‐3p. We further verified that ARL5B also displayed carcinogenic activity in breast cancer cells. Conclusion Our work demonstrated the carcinogenic activity of FTO in promoting the invasion and migration of breast cancer cells via the FTO/miR‐181b‐3p/ARL5B signaling pathway.
Representation of Women as Authors of Rheumatology Research Articles
Authors: Ekta Bagga, Sarah Stewart, Gregory D. Gamble, Janine Hill, Andrew Grey, Nicola Dalbeth
Journal: Arthritis & Rheumatology (2020)

Objective In academic medicine, journal article authorship is central to career advancement and promotion. This study aimed to examine the contemporary representation of women as first and senior authors of rheumatology original research articles. Methods The gender of the first and senior author, disease category, research design, and funding source were extracted from rheumatology original research articles published in high‐impact rheumatology and general medical journals between 2015 and 2019. Results The analysis included 7,651 original research articles. In total, 51.5% of the articles had women first authors (95% confidence interval [95% CI] 50.4–52.6%) and 35.3% had women senior authors (95% CI 34.2–36.4%). Women were significantly less likely to be first and senior authors of articles reporting randomized controlled trials compared with other clinical research designs ( P &lt; 0.001), and of articles reporting industry‐funded/industry‐initiated studies compared with studies not funded by industry ( P ≤ 0.01). Of the articles reporting industry‐funded/industry‐initiated randomized controlled trials, women were first authors in 18.5% (95% CI 13.8–24.0%) and senior authors in 23.9% (95% CI 18.6–29.8%). Conclusion In rheumatology research articles, there is gender parity for first authorship, but women are underrepresented in senior authorship positions. Underrepresentation of women in authorship is particularly apparent in articles reporting randomized controlled trials, and especially those that are initiated by industry.
Prevalence of Psychotropic and Opioid Prescription Fills Among Community-Dwelling Older Adults With Dementia in the US
Authors: Donovan T. Maust, Julie Strominger, Julie P. W. Bynum, Kenneth M. Langa, Lauren B. Gerlach, Kara Zivin, Steven C. Marcus
Journal: JAMA (2020)

This pharmacoepidemiology study uses Medicare data to estimate US prescription fills for antidepressants, anxiolytics, antipsychotics, opioids, and antiepileptics among community-dwelling older adults with dementia in 2014-2015, and identifies the most commonly prescribed medications.
Machine Learning Assessment of Left Ventricular Diastolic Function Based on Electrocardiographic Features
Authors: Nobuyuki Kagiyama, Marco Piccirilli, Naveena Yanamala, Sirish Shrestha, Peter D. Farjo, Grace Casaclang-Verzosa, Wadea M. Tarhuni, Negin Nezarat, Matthew J. Budoff, Jagat Narula, Partho P. Sengupta
Journal: Journal of the American College of Cardiology (2020)
補助シクロホスファミドとビンクリスチンがそのあとに続く放射線療法において放射線増感剤としてカルボプラチンで治療される松果体芽腫患者の結果:COG 99701の序報
Authors: Jakacki R, Zhou T, Holmes E, Packer R, Goldwein J, Mehta M, Pollack I
Journal: Neuro-Oncology (2007)
Deletions and Loss of Expression of P16INK4a and P21Waf1 Genes Are Associated With Aggressive Variants of Mantle Cell Lymphomas
Authors: Magda Pinyol, Luis Hernandez, Maite Cazorla, Milagros Balbı́n, Pedro Jares, Pedro L. Fernandez, Emilio Montserrat, Antonio Cardesa, Carlos Lopez-Otı́n, Elı́as Campo
Journal: Blood (1997)
Abstract 4291: Left Atrial Appendage Occlusion: Early Clinical Results with a New Clip
Authors: Sacha P Salzberg, Andre Plass, Hatem Alkadhi, Jurg Grunenfelder, Rolf Jenny, Michele Genoni
Journal: Circulation (2008)

Background: Atrial fibrillation (AF) is a common arrhythmia and as such a significant risk factor for stroke originating from the left atrial appendage (LAA). The purpose of this study is to evaluate surgical LAA occlusion with a new clip in patients with AF undergoing open heart surgery (OHS) at 3 month follow-up with cardiac multidetector computed tomography (MDCT). Patients and Methods: From 9/2007 to 5/2008, patients undergoing OHS with AF were enrolled in a trial for concomitant clip placement (LAA clip, Atricure Inc., Westchester, Ohio (USA)). The LAA clip is composed of titanium rods with nitinol hinges, surrounded by polyester braiding, applied epicardially on the LAA. LAA geometry and perfusion was assessed by trans-esophageal echocardiography (TEE). Postoperative and 3 month follow-up MDCT was compared to preoperative data to assess Clip location, LAA perfusion and cardiac anatomy. Results: 30 patients underwent LAA Clip placement through a median sternotomy. Clip deployment was successful in all (n=30), no device related complications occurred. LAA measurement and clip placement took less than 30 seconds and one attempt. After deployment TEE confirmed absence of LAA perfusion in all. Operative mortality was 6% (n=2) and was unrelated to clip placement. Pre-discharge (n=28) and 3 month follow-up (n=18) MDCT demonstrated stable clip location, absent LAA perfusion and normal surrounding cardiac structures. Conclusion: LAA Clip occlusionis safe, easy and straightforward. LAA occlusion remains effective and durable, per TEE and MDCT. When applied in a minimally invasive fashion LAA clip occlusion might offer a valuable tool for stroke prevention in selected patients.
Oral Calcium Supplements Associate With Serial Coronary Calcification
Authors: Najdat Bazarbashi, Samir R. Kapadia, Stephen J. Nicholls, Julie Carlo, Mohamed M. Gad, Manpreet Kaur, Antonette Karrthik, Yasser M. Sammour, Mohamed Diab, Keerat Rai Ahuja, E. Murat Tuzcu, Steven E. Nissen, Rishi Puri
Journal: JACC. Cardiovascular imaging (2020)
Biofabrication of a Functional Tubular Construct from Tissue Spheroids Using Magnetoacoustic Levitational Directed Assembly
Authors: Vladislav A. Parfenov, Elizaveta V. Koudan, Alisa A. Krokhmal, Elena A. Annenkova, Stanislav V. Petrov, Frederico D. A. S. Pereira, Pavel A. Karalkin, Elizaveta K. Nezhurina, Anna A. Gryadunova, Elena A. Bulanova, Oleg A. Sapozhnikov, Sergey A. Tsysar, Kaizheng Liu, Egbert Oosterwijk, Henk van Beuningen, Peter van der Kraan, Sanne Granneman, Hans Engelkamp, Peter Christianen, Vladimir Kasyanov, Yusef D. Khesuani, Vladimir A. Mironov
Journal: Advanced Healthcare Materials (2020)

Abstract In traditional tissue engineering, synthetic or natural scaffolds are usually used as removable temporal support, which involves some biotechnology limitations. The concept of “scaffield” approach utilizing the physical fields instead of biomaterial scaffold has been proposed recently. In particular, a combination of intense magnetic and acoustic fields can enable rapid levitational bioassembly of complex‐shaped 3D tissue constructs from tissue spheroids at low concentration of paramagnetic agent (gadolinium salt) in the medium. In the current study, the tissue spheroids from human bladder smooth muscle cells (myospheres) are used as building blocks for assembling the tubular 3D constructs. Levitational assembly is accomplished at low concentrations of gadolinium salts in the high magnetic field at 9.5 T. The biofabricated smooth muscle constructs demonstrate contraction after the addition of vasoconstrictive agent endothelin‐1. Thus, hybrid magnetoacoustic levitational bioassembly is considered as a new technology platform in the emerging field of formative biofabrication. This novel technology of scaffold‐free, nozzle‐free, and label‐free bioassembly opens a unique opportunity for rapid biofabrication of 3D tissue and organ constructs with complex geometry.
Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens
Authors: Sung Won Lim, Song Ee Park, Jangho Cho, Youjin Kim, Hansang Lee, Juhyun Hong, Eunseok Jeon, Jinoh Choi, Gayeon Lee, Byungjun Kim, Ju Hong Min, Jung Sun Kim, Jung Eun Lee, Joon Young Choi, Silvia Park, Seok Jin Kim, Jun Ho Jang, Won Seog Kim, Chul Won Jung, Kihyun Kim
Journal: Blood (2017)
Serum PSA response to lycopene supplementation along with multivitamin does not differ from response to multivitamin alone in men with high grade intraepithelial neoplasia in a randomized trial.
Authors: Alicia C. McDonald, Clareann H. Bunker, Noreen De La Rosa, Jocelyn Matar, Alan L. Patrick
Journal: Cancer Research (2006)

5660  Lycopene, an antioxidant, has been associated with lowering prostate cancer risk. Two clinical trials have shown lower serum prostate specific antigen (PSA) levels, which suggest tumor regression, in pre-prostatectomy men after three weeks of lycopene supplementation. Our study examined whether longer lycopene supplementation lowers serum PSA in Tobago men at high risk for prostate cancer. African-Caribbean men, aged 42–78, from the Tobago Prostate Cancer Screening Survey with pathological evidence of high-grade prostatic intraepithelial (HGPIN), atypical foci, or persistently elevated PSA were eligible to participate in the study. Participants were randomized to vitamin only or 30 mg/day lycopene plus vitamin treatment groups and were followed for 4 months in which serum PSA and lycopene levels were measured at randomization, one month, and four months. To assess the differences between the two treatment groups, t-test and chi-square testing were used. Eight-one men participated in the study, 41 and 40 in the vitamin only and lycopene plus vitamin treatment groups, respectively. There were no significant differences in serum PSA between the two treatment groups. Serum PSA decreased in both groups after the first month of treatment and increased back to randomization levels by month 4. No adverse effects from lycopene supplementation were documented. Our study results demonstrated 4 months of 30 mg/day lycopene supplementation was safe to administer in men with HGPIN, atypia, and elevated PSA. Further studies are needed to evaluate long-term use of lycopene supplementation in reducing prostate cancer risk.
Simultaneous splenectomy improves outcomes after adult living donor liver transplantation
Authors: Tomoharu Yoshizumi, Shinji Itoh, Mototsugu Shimokawa, Shoichi Inokuchi, Noboru Harada, Kazuki Takeishi, Yohei Mano, Shohei Yoshiya, Takeshi Kurihara, Yoshihiro Nagao, Toru Ikegami, Yuji Soejima, Masaki Mori
Journal: Journal of Hepatology (2020)
Noninvasive Hemodynamic Assessment of Shock Severity and Mortality Risk Prediction in the Cardiac Intensive Care Unit
Authors: Jacob C. Jentzer, Brandon M. Wiley, Nandan S. Anavekar, Sorin V. Pislaru, Sunil V. Mankad, Courtney E. Bennett, Gregory W. Barsness, Steven M. Hollenberg, David R. Holmes, Jae K. Oh
Journal: JACC. Cardiovascular imaging (2020)
Additive-lathe 3D bioprinting of bilayered nerve conduits incorporated with supportive cells
Authors: Jingyi Liu, Bin Zhang, Liang Li, Jun Yin, Jianzhong Fu
Journal: Bioactive Materials (2020)

Nerve conduits have been identified as one of the most promising treatments for peripheral nerve injuries, yet it remains unsolved how to develop ideal nerve conduits with both appropriate biological and mechanical properties. Existing nerve conduits must make trade-offs between mechanical strength and biocompatibility. Here, we propose a multi-nozzle additive-lathe 3D bioprinting technology to fabricate a bilayered nerve conduit. The materials for printing consisted of gelatin methacrylate (GelMA)-based inner layer, which was cellularized with bone marrow mesenchymal stem cells (BMSCs) and GelMA/poly(ethylene glycol) diacrylate (PEGDA)-based outer layer. The high viability and extensive morphological spreading of BMSCs encapsulated in the inner layer was achieved by adjusting the degree of methacryloyl substitution and the concentration of GelMA. Strong mechanical performance of the outer layer was obtained by the addition of PEGDA. The performance of the bilayered nerve conduits was assessed using in vitro culture of PC12 cells. The cell density of PC12 cells attached to cellularized bilayered nerve conduits was more than 4 times of that on acellular bilayered nerve conduits. The proliferation rate of PC12 cells attached to cellularized bilayered nerve conduits was over 9 times higher than that on acellular bilayered nerve conduits. These results demonstrate the additive-lathe 3D bioprinting of BMSCs embedded bilayered nerve conduits holds great potential in facilitating peripheral nerve repair.
Co-expression of c-Myc and E2F1 in a mouse model of liver cancer suppresses apoptosis through activation of Akt/mTOR/p70S6K and COX-2 pathways: relevance for human hepatocellular carcinoma
Authors: Sara Ladu, Diego F. Calvisi, Elizabeth A. Conner, Valentina M. Factor, Snorri S. Thorgeirsson
Journal: Cancer Research (2005)

1107  We have previously shown that targeted over-expression of c-Myc or E2F1 in the mouse liver elicits similar oncogenic effects. Here we investigated the effect of c-Myc and E2F1 co-expression on hepatocarcinogenesis. Simultaneous expression of c-Myc and E2F1 in hepatocytes conferred a strong resistance to apoptosis and accelerated liver tumor development in the double transgenic mice when compared with either c-Myc or E2F1 parental lines. The average apoptotic indices in tumors arising in c-Myc/E2F1 mice were about 5-fold lower than in c-Myc mice, and 2-fold lower than in E2F1 mice, implying that over-expression of E2F1 interferes with c-Myc-mediated apoptosis. Importantly, inhibition of cell death was paralleled by a remarkable induction of the Akt/mTOR/p70 S6 kinase pathway in all E2F1 (n=20) and c-Myc/E2F1 (n=30) but not in c-Myc (n=20) HCCs. These data indicate that overexpression of E2F1 in the liver promotes survival of neoplastic hepatocytes through activation of the Akt/mTOR/p70 S6K pathway. In particular, liver tumors from E2F1 and c-Myc/E2F1 transgenic mice showed overexpression of Akt, mTOR, p70S6K, elF4E, and elF4G with concomitant inactivation of GSK-3β, BAD, and 4E-BP1. On the other hand, all c-Myc/E2F1 HCCs displayed upregulation of COX-2 and COX-2 target genes, such as Mcl-1 and bcl-2, whereas the same pathway was rarely activated in E2F1 (5/20, 25%) and not induced in c-Myc HCCs. Activation of COX-2 in c-Myc/E2F1 HCCs led to suppression of Trail-mediated apoptosis, including downregulation of DR5 and inhibition of cytochrome C release and caspase 8 activation. Subsequent analysis of thirty four human HCCs and corresponding surrounding non-tumorous tissues showed that the Akt/mTOR/p70S6K and COX-2 pathways were constitutively activated in all human liver tumors. Taken together, these data demonstrate that co-expression of c-Myc and E2F1 enhances liver tumorigenesis mainly through activation of Akt/mTOR/p70S6K and COX-2 pathways, which results in suppression of apoptosis. The c-Myc/E2F1 model may be useful in validating the efficacy of antineoplastic strategies leading to the suppression of Akt and COX-2 pathways in human hepatocellular carcinoma.
Determination of bioavailable drug levels from liposomal doxorubicin in murine orthotopic breast tumors
Authors: Theresa M. Allen, Kim Laghina, Gregory J. Charrois, Sylvia Verwoert
Journal: Cancer Research (2004)

631  Two liposomal formulations of doxorubicin (DXR), CaelyxR and MyocetR, having very different physical properties and side effects, have received clinical approval for the treatment of refractory breast cancer. Drugs entrapped in liposomes are not bioavailable - they must be released to exhibit activity. The rate at which the drugs are released and the site of release will, we hypothesize, have significant effects on both the therapeutic activity of the formulations and their side effects. To date, only methods to measure total drug in solid tumors (liposomal + released drug) have been available. We have devised methods to also measure bioavailable (released) drug. Total drug was determined in orthotopically implanted murine breast cancer tumors by acidified isopropanol extraction of tumor homogenates at various times after treatment with either liposomal or free DXR. Since only released DXR can reach tumor nuclei and intercalate with DNA, released drug was measured by extracting intercalated drug from nuclei purified from tumor homogenates. After administration of free DXR to tumor-bearing mice, tumor levels of total DXR and nuclear DXR were very similar (i.e., nearly 100% bioavailable), and peak levels for both occured by the first time point (12 h). Total DXR levels in tumor for mice administered free DXR (18 mg/kg) were approximately 50-fold lower than total DXR levels for mice administered liposomal DXR (Caelyx). Peak levels of total drug from liposomal DXR occured at 24 h post-administration, while peak levels of nuclear DXR were delayed until 48-72 h post-administration. Over 7 days, approximately 40% of DXR from liposomal DXR was bioavailable. It is now possible to correlate the levels of bioavailable drug with therapeutic activity for liposomes having different sizes, compositions and release rates. These studies will be supplemented with apoptotic assays and will help to guide the rational design of drug carriers.
Deep learning for automated sleep staging using instantaneous heart rate
Authors: Niranjan Sridhar, Ali Shoeb, Philip Stephens, Alaa Kharbouch, David Ben Shimol, Joshua Burkart, Atiyeh Ghoreyshi, Lance Myers
Journal: npj Digital Medicine (2020)

Abstract Clinical sleep evaluations currently require multimodal data collection and manual review by human experts, making them expensive and unsuitable for longer term studies. Sleep staging using cardiac rhythm is an active area of research because it can be measured much more easily using a wide variety of both medical and consumer-grade devices. In this study, we applied deep learning methods to create an algorithm for automated sleep stage scoring using the instantaneous heart rate (IHR) time series extracted from the electrocardiogram (ECG). We trained and validated an algorithm on over 10,000 nights of data from the Sleep Heart Health Study (SHHS) and Multi-Ethnic Study of Atherosclerosis (MESA). The algorithm has an overall performance of 0.77 accuracy and 0.66 kappa against the reference stages on a held-out portion of the SHHS dataset for classifying every 30 s of sleep into four classes: wake, light sleep, deep sleep, and rapid eye movement (REM). Moreover, we demonstrate that the algorithm generalizes well to an independent dataset of 993 subjects labeled by American Academy of Sleep Medicine (AASM) licensed clinical staff at Massachusetts General Hospital that was not used for training or validation. Finally, we demonstrate that the stages predicted by our algorithm can reproduce previous clinical studies correlating sleep stages with comorbidities such as sleep apnea and hypertension as well as demographics such as age and gender.